Accrol Group Holdings PLC Regulatory Investigation Update (1694U)

TIDMACRL

RNS Number : 1694U

Accrol Group Holdings PLC

27 March 2019

27 March 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Accrol Group Holdings plc

("Accrol" or the "Company")

Regulatory Investigation Update

Further to the announcement dated 21 January 2019, entitled "Regulatory Investigation" (RNS number 6698N), the FCA has notified Accrol that the period it is investigating has been revised from 1 April 2017 to 20 November 2017 to 10 June 2016 to 30 September 2018, to cover the period from the date Accrol's share capital was admitted to trading on AIM to the date the Company's audited accounts for the year ended 30 April 2018 ("2018 Accounts") were made public. The 2018 Accounts identified misstatements in the previously published accounts for the period 1 May 2016 to 30 April 2017.

 
For further information, please contact: 
 
Accrol Group Holdings plc 
Dan Wright, Executive Chairman              Tel: [phone] 
Gareth Jenkins, Chief Executive Officer 
 
Zeus Capital Limited (Nominated Adviser 
 & Broker) 
Dan Bate / Andrew Jones                     Tel: [phone] 
Dominic King / John Goold                   Tel: [phone] 
 
Belvedere Communications Limited 
Cat Valentine ([e-mail])  Tel: [phone] 
Keeley Clarke ([e-mail])     Tel: [phone] 
Llew Angus ([e-mail])           Tel: [phone] 
 

Notes to Editors

Accrol Group Holdings plc, based in Lancashire, is a leading tissue converter and supplier of toilet rolls, kitchen rolls and facial tissues, as well as other tissue products, to major discounters and grocery retailers throughout the UK. Accrol operates from three sites:

 
 --   A manufacturing, storage and distribution 
       facility in Blackburn; 
 --   A facial tissue plant, also in Blackburn; 
       and 
 --   A manufacturing, storage and distribution 
       facility in Leyland. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAEDXAFXNEFF

(END) Dow Jones Newswires

March 27, 2019 06:20 ET (10:20 GMT)